牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals Plc, a public limited company organized under the laws of England and Wales, has successfully completed an exempt offering of securities, as indicated in a new Form D notice filed with the U.S. Securities and Exchange Commission (SEC). The offering, which was not subject to review by the SEC for accuracy, raised a total of $6,793,406 USD. The date of the first sale was reported as December 21, 2023, and the offering was completed without any remaining securities to be sold. Biodexa Pharmaceuticals, with its principal place of business in Cardiff, United Kingdom, has declined to disclose its revenue range or aggregate net asset value. The securities offered included equity, options, warrants, or other rights to acquire another security, and...Show More
Biodexa Pharmaceuticals Plc, a public limited company organized under the laws of England and Wales, has successfully completed an exempt offering of securities, as indicated in a new Form D notice filed with the U.S. Securities and Exchange Commission (SEC). The offering, which was not subject to review by the SEC for accuracy, raised a total of $6,793,406 USD. The date of the first sale was reported as December 21, 2023, and the offering was completed without any remaining securities to be sold. Biodexa Pharmaceuticals, with its principal place of business in Cardiff, United Kingdom, has declined to disclose its revenue range or aggregate net asset value. The securities offered included equity, options, warrants, or other rights to acquire another security, and securities to be acquired upon the exercise of options, warrants, or other rights. The company's executive officers and directors, including CEO and CFO Stephen Stamp, were named in the filing. The offering did not involve any sales compensation such as broker or dealer commissions or finders' fees, and the proceeds will not be used for payments to any executive officers, directors, or promoters. Biodexa Pharmaceuticals has claimed an exemption under Rule 506(b) of the Securities Act and has confirmed that the offering will not last more than one year.
正如向美國證券交易委員會（SEC）提交的新表格D通知所示，根據英格蘭和威爾士法律組建的上市有限公司Biodexa Pharmicals Plc已成功完成證券的豁免發行。此次發行的準確性沒有經過美國證券交易委員會的審查，共籌集了6,793,406美元。據報道，首次出售的日期爲2023年12月21日，此次發行已完成，沒有任何剩餘證券可供出售。主要營業地點位於英國加的夫的Biodexa Pharmicals拒絕透露其收入範圍或總淨資產價值。提供的證券包括股權、期權、認股權證或其他收購其他證券的權利，以及在行使期權、認股權證或其他權利時收購的證券。文件中提名了該公司的執行官和董事，包括首席執行官兼首席財務官斯蒂芬·斯坦普。此次發行不涉及任何銷售補償，例如經紀人或交易商佣金或發現者費用，所得款項將不用於向任何執行官、董事或發起人付款。Biodexa Pharmicals已根據《證券法》第506（b）條申請豁免，並確認此次發行不會超過一年。
正如向美國證券交易委員會（SEC）提交的新表格D通知所示，根據英格蘭和威爾士法律組建的上市有限公司Biodexa Pharmicals Plc已成功完成證券的豁免發行。此次發行的準確性沒有經過美國證券交易委員會的審查，共籌集了6,793,406美元。據報道，首次出售的日期爲2023年12月21日，此次發行已完成，沒有任何剩餘證券可供出售。主要營業地點位於英國加的夫的Biodexa Pharmicals拒絕透露其收入範圍或總淨資產價值。提供的證券包括股權、期權、認股權證或其他收購其他證券的權利，以及在行使期權、認股權證或其他權利時收購的證券。文件中提名了該公司的執行官和董事，包括首席執行官兼首席財務官斯蒂芬·斯坦普。此次發行不涉及任何銷售補償，例如經紀人或交易商佣金或發現者費用，所得款項將不用於向任何執行官、董事或發起人付款。Biodexa Pharmicals已根據《證券法》第506（b）條申請豁免，並確認此次發行不會超過一年。
有用
沒用